COVID-19 Funding Opportunities

Texas Higher Education Coordinating Board (THECB)

Nursing Innovation Grant Program (NIGP)

Biomedical Advanced Research and Development Authority (BARDA) Novel Coronavirus EZ-BAA

Department of Homeland Security (DHS)

Innovative Commercial Products in Support of Coronavirus (COVID-19) Response – Commercial Solutions Opening Pilot Program (CSOP)

Topics: Proposed innovative commercial products may be, but are not limited to, products that:

• Supplement shortages and/or emerging needs for personal protective equipment
• Enhance or expedite screening capabilities
• Enhance or expedite facility cleaning capabilities
• Extend testing capabilities
• Utilize technology to support the COVID-19 response
• Convert existing production and logistics operations to support the COVID-19 response.

White House Office of Science and Technology Policy

COVID-19 High Performance Computing (HPC) Consortium

This consortium is a unique private-public effort to bring together federal government, industry, and academic leaders to execute complex computational research programs. Researchers are invited to submit COVID-19 related research proposals to the consortium via this online portal, which will then be reviewed for matching with computing resources from one of the partner institutions. An expert panel comprised of top scientists and computing researchers will work with proposers to assess the public health benefit of the work, with emphasis on projects that can ensure rapid results.
XSEDE Website

Food and Drug Administration (FDA)/Office of the Chief Scientist (OCS)

and Center for Drug Evaluation and Research (CDER)

Drug Development Science Support (U01)

The Food and Drug Administration (FDA) Office of the Chief Scientist (OCS) and FDA Center for Drug Evaluation and Research (CDER), Office of Medical Policy (OMP) is announcing its intent to accept and consider applications for the award of a co-operative agreement to protect and promote the health of the American public by creating new, applied scientific knowledge, tools, standards and approaches to evaluate products more effectively, predictably and efficiently.

National Endowment for the Humanities (NEH)

Funding for NEH Applicants and Grantees Impacted by the Coronavirus

NEH plans to announce funding opportunities for eligible organizations seeking support for at-risk humanities positions and projects at cultural nonprofits  that have been impacted by the coronavirus. 

Office of the Assistant Secretary for Preparedness and Response (ASPR)

Public Health Emergency development of new medical countermeasures

Public Health Emergency development of new medical countermeasures

National Institutes of Health (NIH)

Agency for Healthcare Research and Quality (AHRQ)

 Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19

The health systems research community should prepare to submit applications to AHRQ to fund critical research focused on evaluating topics such as innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic.  AHRQ is particularly interested in understanding how digital health innovations contributed to health system and healthcare professional innovation and challenges and solutions to meeting the needs of vulnerable populations including older adults, people living with multiple chronic conditions, rural communities, and uninsured and underinsured populations.

 National Institutes of Health (NIH)

National Institute of Allergy and Infectious Diseases (NIAID)

Notice of special interest – availability of emergency competitive revisions for research on severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019

03/25/2021

This supports research on coronavirus disease with a particular focus on viral natural history, pathogenicity and transmission. The maximum project duration is two year

 National Institutes of Health (NIH)

National Center for Advancing Translational Sciences (NCATS)

Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to Address COVID-19 Public Heath Need

 11/10/2020

 The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the need for projects that address the coronavirus disease 2019 (COVID-19) Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS is soliciting applications for Administrative Supplements (through PA-18-591) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients.

National Institutes of Health (NIH)

National Institute on Aging (NIA), National Institute of Mental Health (NIMH)

 NOSI Regarding Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

NIA – Mission critical areas as they relate to the COVID-19 pandemic. NIMH – Applications addressing care for new or worsening mental health needs and/or suicide risk in midlife and older age adults will be seen as a high priority.

• PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements for NIH grantees applying to expand the scope of their active grant.
  
  
• PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.

National Institutes of Health (NIH)

Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

The purpose of this SEBI NOSI is to identify, analyze, and address the social, ethical, and behavioral factors likely to influence access and uptake of COVID-19 testing in underserved and/or vulnerable populations. Single or mixed methods approaches involving community partners will inform the development and evaluation of such testing programs. These studies will assess the ethical, historical, healthcare, social and contextual factors surrounding COVID-19 testing, as well as how cultural beliefs and attitudes, perceived expectations, and preferences influence the ability and willingness to get tested and participate in follow-up evaluations. Findings will be used to develop interventions to mitigate barriers to access and increase uptake of testing. Studies focused on unintended consequences of COVID-19 testing in these groups are also of interest when related to social and ethical issues.

The related program initiatives include:

• NOT-OD-20-121which encourages community-engaged Testing Research Projects to supplement large scale networks, consortia, or centers, will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods.
• NOT-OD-20-120 with a similar focus, but shifts the pool of eligible grants for supplementation to individual research awards that include community collaboration or partnership, generally targeting specific populations.
• RFA-OD-20-013 which is a U24 Coordination and Data Collection Center (CDCC) as a key component of the consortium

 National Institutes of Health (NIH)

Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency caused by Coronavirus Disease 2019 (COVID-19)

The purpose of this Notice is to extend the data-harmonization effort at the National Institute of Mental Health (NIMH) announced in NOT-MH-15-009 to research protocols pertaining to the public health emergency caused by Coronavirus Disease 2019 (COVID-19), the disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

National Institutes of Health (NIH)

National Institute on Aging (NIA)

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities

 
The National Institute on Minority Health and Health Disparities (NIMHD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.

National Institutes of Health (NIH)

R01, R21, SBIR/STTR for COVID-19

Three of the largest NIH parent/umbrella funding mechanisms have now been updated to indicate that applications pertaining to COVID-19 research are welcomed.

National Institutes of Health (NIH)

National Heart, Lung, and Blood Institute (NHLBI)

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

National Institute of Allergy and Infectious Diseases (NIAID)

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)

RADx-UP

NOSI: Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

As part of the RADx-UP initiative, the NIH has announced a SEBI NOSI for projects to identify, analyze, and address the social, ethical, and behavioral factors likely to influence access and uptake of COVID-19 testing in underserved and/or vulnerable populations.

Topics: 

• Which social, ethical and behavioral facilitators and barriers substantially influence decisions about whether and when to offer or seek COVID-19 testing?
• What strategies mitigate barriers, and increase access to and acceptability of testing and repeat testing?
• What are implications of both positive and negative COVID-19 diagnostic tests for underserved and/or vulnerable groups, and how do they influence testing decisions and downstream beliefs and behaviors?
• How are test results interpreted and used in these underserved and/or vulnerable communities?
• What are the risks and benefits of implementing new COVID-19 testing technologies in underserved and/or vulnerable communities from the perspectives of those populations?
• What population specific social, ethical, or behavioral factors should be addressed before deploying novel testing strategies?
• What factors should be addressed before vaccine trials can be considered?
• What strategies can be developed and tested to increase acceptability of vaccine trials and vaccinations in underserved and/or vulnerable populations?

Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional) (NIH)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Allergy and Infectious Diseases (NIAID)

NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19). Applications on the following priority topics are invited:

• Efficacy and safety of interventions that target aging-related biological mechanisms that may influence risk or severity of COVID-19 infection among at-risk older adults
• Efficacy and safety of preventive and treatment interventions in older patients with differing comorbid conditions that make them especially vulnerable to adverse outcomes of COVID-19 infection
• Effectiveness of health and/or custodial care practices to reduce transmission risk or improve outcomes of COVID-19 infection in nursing homes or other residential settings serving at-risk older persons, including the development and testing of infection control training procedures for healthcare workers
• Rapid pragmatic trials in (at least two) health systems, nursing homes, or adult living facilities, ensuring replication across large pragmatic trial sites and leveraging electronic health records to promote quality improvement in physician, hospital, palliative care, and hospice practices to improve outcomes for older patients with COVID-19, especially those with cognitive impairment, Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD), or underlying comorbidities
• Trials in at-risk older adults age 65 and older for whom electronic medical records are available and long-term outcomes can be tracked, and in institutions serving those populations
• Trials in older adults with AD/ADRD, older adults from populations with NIH-defined health disparities, and/or other vulnerable populations (e.g. incarcerated, homeless, living in institutions)

National Institute of General Medical Sciences (NIGMS)

Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19

Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations

Key questions include: To what extent do existing interventions slow the spread of COVID-19 in specific populations and geographic hotspots? To what extent do policies, guidelines, and other interventions facilitate adherence and mitigate the multifaceted impacts of COVID-19 on health in populations that experience health disparities and vulnerable groups? Can established models of crisis and disaster response and management be applied to address the needs of health disparity and other vulnerable populations?

• The effects of prolonged oral intubation on laryngeal function and voice production
• Short-term and long-term effects of COVID-19 on the auditory, vestibular or olfactory systems
• The prevalence, onset, and resolution of acquired deficits (i.e. HBTSVSL) among patients with COVID-19 across the lifespan and in association with various underlying genetic predispositions and health conditions
• The molecular mechanisms underlying chemosensory dysfunction due to SARS-CoV-2 infection
• The impact of stress/isolation on speech, language or fluency recovery/development in children or adults
• The impact of potential congenital transmission of maternal SARS-CoV-2 infection to the newborn in relation to the auditory, vestibular, olfactory, or vocal function and/or the impact on speech production or language acquisition
• Potential ototoxicity from therapeutics or vaccination related to COVID-19
• Worsening of communicative function because of physical distancing, sheltering in place, and wearing of protective personal equipment during mitigation of this infectious pandemic
• Telehealth service delivery to individuals with communication disorders
• Multidisciplinary collaborative teams including clinicians, basic biologists, geneticists, quantitative scientist, epidemiologists or other researchers to study COVID-19 related human conditions and behaviors, bioethical considerations, health-service delivery, health services in low-resource areas, and health disparities within NIDCD mission areas

National Center for Advancing Translational Sciences (NCATS)

NOSI: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

Topics: Use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

• PA-18-591  Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

National Institutes of Health (NIH)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

 The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years

National Center for Advancing Translational Sciences (NCATS)

NOSI: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

Topics: Use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. 

• PAR-19-099 Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)

•  PAR-19-100 Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)

National Center for Advancing Translational Sciences (NCATS)

NOSI: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

Topics: Use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

•  PAR-19-337 Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional).

Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

Topics: Using innovative processes to identify the therapeutic/indication pair for use to treat COVID-19.

• PA-18-462 Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications from current grantees to develop life-saving technologies that can be ready for commercialization within one to two years.

Notice of special interest – emergency competitive revisions and administrative supplements to clinical and translational science award programme awards to address 2019 novel coronavirus disease (COVID-19) public health needs

This supports projects in translational science that address the COVID-19 public health emergency. Up to 40 awards are available. Supplement grants are generally for a maximum period of one year

Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

Topics: Using innovative processes to identify the therapeutic/indication pair for use to treat COVID-19.

• PAR-18-332 Clinic Testing Therapeutic/Indications Pairing Strategies (U01 Clinical Trial Required)

NOSI: Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs

Topics:

• Digital health platforms
• Planning of COVID-19 trials
• eConsent support
• Platforms for meta-analysis of COVID-19 trials
• Clinical data provision
• Clinical studies and trials of COVID-19 interventions
• Assessment of infectious or convalescent status

National Institute of Drug Abuse (NIDA)

National Institutes of Health (NIH)

Agency for Healthcare Research and Quality (AHRQ)

Special Emphasis Notice (SEN): AHRQ Announces Interest in Research on Improving Organizational Health Literacy to Prevent and Manage Chronic Disease

 This Special Emphasis Notice (SEN) highlights AHRQ’s interest in receiving applications focusing on primary and other ambulatory care settings that: 1) test approaches to integrating organizational health literacy strategies that make it easier for people, especially those with limited health literacy, to take action to prevent and manage their chronic conditions, including diabetes, and 2) spread and scale previously tested organizational health literacy strategies to settings that serve a high proportion of patients with limited health literacy, and/or socioeconomically disadvantaged people.AHRQ is interested in applications that address:

• Which approaches for implementing organizational health literacy strategies, and in which ambulatory settings, are effective in improving prevention and management of chronic diseases for diverse people with limited health literacy
• How healthcare organizations can best adopt, adapt, implement, and scale and spread health literacy strategies to improve prevention and management of diabetes and other chronic diseases for people with limited health literacy

National Institutes of Health (NIH)

National Institute of Environmental Health Sciences (NIEHS)

Notice of special interest – support for understanding the impact of environmental exposures on coronavirus disease

This supports research aimed at understanding the impact of environmental exposures on coronavirus disease and its causative agent. Funding may last for up to two years.

National Institutes of Health (NIH)

National Institute of Environmental Health Sciences (NIEHS)

Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)

NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

National Institutes of Health (NIH)

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)

 The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

National Institutes of Health (NIH)

NIH Rapid Acceleration of Diagnostics (RADx) Initiative for COVID-19

The stimulus investment supercharges NIH’s strong research efforts already underway focused on prevention and treatment of COVID-19, including the recently announced planned Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership to coordinate the international research response to the pandemic.  

As part of this initiative, NIH is urging all scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to $500 million over all phases of development. The technologies will be put through a highly competitive, rapid three-phase selection process to identify the best candidates for at-home or point-of-care tests for COVID-19. 

National Institutes of Health (NIH)

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

National Institutes of Health (NIH)

National Institute of Allergy and Infectious Diseases (NIAID)

Emergency awards – rapid investigation of severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 (R21 clinical trial not allowed)

These support research projects focusing on obtaining time-sensitive data to better understand key aspects of severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019. Application budgets are limited to USD 275,000 for two years.

National Institutes of Health (NIH)

Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01) 

 While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations

National Institutes of Health (NIH)

National Institute of Allergy and Infectious Diseases (NIAID)

Emergency awards – rapid investigation of severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 (R01 clinical trial not allowed)

These support research on SARS-CoV-2 and COVID-19. The maximum project period is five years.

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

This Notice announces the availability of competitive revisions for investigators and institutions funded through:

• The NIH Microphysiological Systems (MPS) Program; or
• SBIR/STTR-supported investigators, provided the award involves tissue chips; or
• Microphysiological systems programs from across NIH.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs

National Cancer Institute (NCI)

National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)

Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)

 The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for Coronavirus Disease 2019 (COVID-19). To accelerate the development of promising technologies, the NCI encourages applications from small businesses with NCI-funded active SBIR/STTR awards for technologies that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19).

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences

 This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts,including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System

NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

In order to rapidly improve our understanding of the neurological consequences of infection of SARS-CoV-2 and of COVID-19, NINDS is encouraging the submission of applications for supplements to address the biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronovirus that are directly related to the NINDS mission.

Notice of special interest – clinical and translational science award programme applications to address 2019 novel coronavirus public health need

This supports research on the 2019 novel coronavirus, with a particular focus on the use of informatics solutions to diagnose cases and advancing the translation of research findings into diagnostics, therapeutics and vaccines. The project duration is limited to the remaining active budget period for the parent award.

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Notice of special interest – administrative supplements and competitive revision supplements on coronavirus disease 2019 within the mission of the NIAAA

This supports research on the impact of alcohol as a biological contributor to COVID-19 outcomes in order to enhance the response to the pandemic and better respond to future public health emergencies. Budgets are worth up to USD 100,000 in direct costs per year for up to two years.

National Institute of Mental Health (NIMH)

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus

 NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.

Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA

 NIAAA is encouraging research in the following areas, including those that capitalize on existing research cohorts, to investigate urgent research questions of significance to the COVID-19 pandemic within the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless.

National Institute of Dental and Craniofacial Research (NIDCR)

NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR

Topics:

• Prevention of SARS-COV-2 transmission
• Improvements in the detection and diagnosis of COVID-19
• Acquisition of a more robust understanding of SARS-CoV-2 pathogenesis
• Influence and interaction of sex (a biological variable) and gender (a social construct), race and ethnicity in relation to COVID-19
• COVID-19 risk, prevention, and health outcomes

Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)

Topics: 

• Development and deployment of standardized and validated over-the-counter testing kits or tests that utilize common household items for remote, home-based screening through telemedicine for mildly to moderately affected individuals.
• Modification of existing test platforms (e.g., NIH Toolbox) to improve the efficiency of administration, data collection, and evaluation using mobile phone apps and telemedicine.
• Development of innovative chemosensory platforms that can be implemented for the testing of large, at-risk populations, for example, health care workers, pregnant women, and older adults and caretakers residing/working at nursing homes and long-term care facilities.
• Establishment of appropriate odorants, optimal odorant concentrations, and standardized delivery systems and protocols for the development of onsite, group testing stations for those working or living in high-density, high-risk environments.
• Analysis of test results to determine the specificity of chemosensory testing with respect to COVID-19 versus influenza, the onset of chemosensory dysfunction, and the prognostic value of chemosensory testing in predicting neurological and other manifestations

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed)

 Topics: Biosensing and detection technologies submitted to this initiative should provide associations between biomarkers emanating from skin or the oral cavity to patients with symptomatic and asymptomatic COVID-19. Leveraging the accessibility of human skin and the oral cavity, this FOA seeks 1) to advance novel biosensing technologies that are innovative, safe, and effective, and 2) to implement such technologies into devices with integrated artificial intelligent (AI) systems for the detection, diagnosis, prediction, prognosis and monitoring of COVID-19 in clinical, community and everyday settings. Skin biosensing designs must target detection of volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin in a passive and noninvasive manner for use at point of care. In addition to VOCs, oral biosensing technologies may target a wealth of biological, chemical and physical biosignatures representative of SARS-CoV-2 virus and/or COVID-19 disease sampled from exhaled breath/droplets, saliva, and tissues in the oral cavity using a variety of detection schemes.

Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 – Clinical Trials Not Allowed)

 Topics: The RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) FOA will support wastewater-based testing (WBT) surveillance that can provide detailed mapping of the extent and spread of COVID-19.

Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)

 Topics: Development of a platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real time. The use of aptamers to detect SARS-CoV-2 is of particular interest.

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)

 Topics: Portable devices for COVID-19 diagnosis using volatile organic compound detection methods

Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)

Topics: SARS-CoV-2 detection via single-vesicle or exosome technologies

Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)

 Topics: Development of a sensing device that can associate VOC patterns with symptomatic and asymptomatic COVID-19 patients and actively detect VOCs from skin and oral cavities of COVID-19 patients without being invasive or affecting the integrity of the skin and oral cavity. For VOC monitoring, the sensing device can utilize Electronic-nose (E-nose) technology or Gas Chromatography (GC). This FOA seeks to advance novel biosensing technologies that use integrated artificial intelligence, pattern recognition and machine learning systems that would make it possible to detect, diagnose, predict, and monitor COVID-19 in clinical, community and everyday settings.

Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)

Topics:

1. Rapid diagnosis and characterization of the spectrum of MIS-C associated with SARS-CoV-2
2. Accurate risk-stratification and prediction of severe disease (MIS-C) outcomes along the spectrum of SARS-CoV-2 exposure and/or infection and throughout the course of illness

Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)

 Topics: Proposals are sought to establish the RADx-rad Data Coordination Center (DCC), which will provide overarching support and guidance to RADx-rad awardees in the following three areas: (1) Administrative Operations and Logistics, (2) Data Collection, Integration and Sharing, and (3) Data Management and Use.

Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)

 Topics: Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses

Agency for Health Care Research and Quality (AHRQ) 

Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement – Clinical Trial Optional)

For grants that were previously funded under FOAs supported by Patient Centered Outcome Research Trust Fund (PCOR TF) dollars, please see FOA number PA-20-072.

For grants that were funded using AHRQ Health Service Research (HSR) dollars, please see FOA number PA-20-070.

Topics: Applications must be responsive to AHRQ’s mission. AHRQ’s Research Priority Areas are:

1. Research to improve health care patient safety.
2. Harnessing data and technology to improve health care quality and patient outcomes and to provide a 360-degree view of the patient.
3. Research to increase accessibility and affordability of health care by examining innovative market approaches to care delivery and financing.

National Science Foundation (NSF)

NSF is seeking Phase I SBIR/STTR proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis.

National Science Foundation (NSF)

Dear Colleague Letter on the Coronavirus

The NSF encourages investigators to use existing NSF funding mechanisms to submit proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.For proposals of up to $200K, NSF encourages using the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency.

The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

Department of Commerce (DOC)

National Institute of Standards and Technology (NIST)

Topic: NIST invites Manufacturing USA institutes to propose high-impact projects designed to respond to the COVID-19 pandemic

Department of Defense (DOD)

Congressionally Directed Medical Research Programs (CDMRP)

Three of the FY20 PRMRP mechanisms are focused on Emerging Viral Diseases and Respiratory Health.

Mechanisms:

• Clinical Trial Award
• Investigator-Initiated Research Award
• Technology/Therapeutic Development Award

Department of Defense (DOD)

Medical Technology Enterprise Consortium (MTEC)

Development of Treatments for COVID-19

MTEC is an enterprise partnership in collaboration with industry and academia to facilitate research and development activities, in cooperation with the U.S. Army Medical Research and Development Command (USAMRDC) and other DoD agencies in the biomedical sciences MTEC membership is not required for proposal submission, but it is required for an award.

Department of Defense (DOD)

Medical Technology Enterprise Consortium (MTEC)

This program is specifically focused on preparation for COVID-19 related critical care capability shortages.  Although the United States has more critical care beds per capita than other developed nations, emerging national and international experience with COVID-19-related critical illness suggests a high level of oncoming system stress on critical care resources and a likely potential for intensive care unit (ICU) beds and care teams to be overwhelmed.

Department of Energy (DOE)

Department of Energy (DOE)

US Department of Agriculture (USDA)

Topics: Focus areas of interest include, but are not limited to the following:

• Animal Nutrition, Growth and Lactation (A1231)
• Critical Agricultural Research and Extension (CARE) (A1701)
• Diseases of Agricultural Animals (A1221)
• Food Safety and Defense (A1332)
• Foundational Knowledge of Plant Products (A1103)
• Economics, Markets, and Trade (A1641)

 This Annual Program Statement (APS) is designed to describe and provide a process through which organizations can work with USAID and the private sector to build GDAs that:

a) respond to the current outbreak of COVID-19 in Bangladesh;

b) address important business interests and objectives; and

c) advance USAID’s strategic priorities and objectives.

National Institute of Standards and Technology (NIST)

Schmidt Futures

The Futures Forum on Learning: Tools Competition

Topics: Solutions should aim to address one of the problem areas:

• Increase the number of students who are reading by 3rd grade
• Increase the number of students on track in middle-school math
• Expand the number of students gaining data and computer science skills in high school
• Driving more students into college through academic and nonacademic supports
• Another pressing learning goal identified by the team that is related to COVID-19

Coalition for Epidemic Preparedness Innovation (CEPI)

Topic: Vaccine and adaptive epidemic response platform development

Bill & Melinda Gates Foundation

 The COVID-19 Therapeutics Accelerator is a collaborative effort to research, develop and bring effective treatments to market quickly and accessibly.Currently there are no broad-spectrum antivirals or immunotherapies available for the fight against emerging pathogens, and no proven treatments approved for use against COVID-19.

The COVID-19 Therapeutics Accelerator is a philanthropic initiative designed to coordinate R&D efforts, remove barriers to drug development and scale up treatments to address the pandemic.We can combat COVID-19 together. Sharing knowledge and resources across governments, the private sector, academia and philanthropy can accelerate the timeline for bringing treatments to market. We are actively seeking and welcoming new partners and collaborators in this effort

American Heart Association (AHA)

Rapid Response Grant COVID-19 and Its Cardiovascular Impact

 Coronavirus infection (coronavirus disease, COVID-19) shows no signs of abating soon. There is an urgent need to better understand the pathobiology and the clinical implications of the viral infection that leads to the morbidity and mortality seen with COVID-19.

LifeArc

Coronavirus therapeutics – call for rapid deployment

LifeArc invites applications for its coronavirus therapeutics call. This supports the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. The primary purpose is to accelerate availability of treatments for patients and it is therefore expected that applicants will already have material available for testing and a plan for rapid scale up of clinical material. Priority will be given to projects that have a clear path and availability for patients in a 6-12 month timeframe.

Arts and Humanities Research Council

Urgency grants pilot

This enables arts and humanities researchers to respond in an agile way to unanticipated urgent research needs and opportunities that meet a development need or challenge, or have the potential to support LMICs to address the UN sustainable development goals. Proposals may have eligible costs of up to £150,000 for up to one year and are funded at 80 per cent of full economic costs

California Institute for Regenerative Medicine

Topics: Discovery, preclinical, and clinical trial stage projects that could quickly advance treatments to COVID-19 patients in need.

Emergent Ventures

Fast Grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.

Wellcome Trust

Wellcome, in partnership with the Department for International Development, invites expressions of interest for its epidemic preparedness - COVID-19 funding call. This aims to strengthen the evidence base to better prevent and control coronavirus (COVID-19) epidemics and increase research and response capacity. 

Open Society Foundations

Aid People Hardest Hit by COVID-19 Pandemic

The Open Society Foundations are making an investment to combat the devastation in the wake of the coronavirus—focusing on communities too often left out and left back by government policy.

This COVID-19 Artist Emergency Fund will provide rapid response grants up to $500 to assist artists with basic needs including food, immediate health needs and insurance premiums. Applications are now open and will be reviewed on a rolling basis until the fund is expired. These one-time grants are a direct response to concerns about sustainability in the documentary field, with overall lack of adequate healthcare alongside loss of livelihood due to canceled production, festivals and theatricals.

 Home Grown

Home-Based Child Care Emergency Fund

As our nation faces the COVID-19 pandemic, the importance of home-based child care has never been more evident and these caregivers and providers have never been more indispensable. We cannot fight this pandemic without ensuring that the essential workforce can access safe, high-quality child care. Without immediate action to maintain the supply of home-based child care, our near term efforts to rebuild the economy will likely be stalled.

Chan Zuckerberg Initiative

Novartis

COVID-19 Relief Fund

To help address the concerns of the industry during this time, we have expanded our services to include lost income due to the cancellation of scheduled gigs or performances due to Coronavirus/COVID-19 precautionary measures.

COVID-19 Opportunity: COVID-19 Therapeutics Accelerator

The Bill & Melinda Gates Foundation, Wellcome and Mastercard today committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The partners are committed to equitable access, including making products available and affordable in low-resource settings. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. Currently, there are no broad-spectrum antivirals or immunotherapies available for the fight against emerging pathogens, and none approved for use on COVID-19.

PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects

PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis through enhancements of currently funded PCORI research awards.

Only PCORI-funded principal investigators with active research project funding contracts are eligible to submit a proposal in response to this announcement.

Google Cloud Research Credits

A total of $20 million in Google Cloud research credits will be provided for leveraging Google’s computing capabilities and infrastructure to study therapies, vaccines, etc.

open donation request program

Amgen has announced an open donation request program providing direct cash grants as well as lab supplies and equipment pertaining to COVID-19 relief; non-profits, IHEs, and health providers are welcome to apply. 

CETF

Topics: CETF seeks research funding to find an existing drug or drug combination that, when given early, can reduce COVID-19 hospitalization and fatality rates by 75% or more

CHEST Foundation

The CHEST Foundation has announced two new COVID-19 programs: the CHEST Foundation and American Thoracic Society Research Grant in COVID-19 and Diversity program and the CHEST Foundation Research Grant in COVID-19 program, both of which require research proposals to address clinical (hospital or outpatient) or community-related aspects of COVID-19. Grants are up to $25,000.

CEPI

Topic: CEPI invites applicants to submit proposals for projects to develop vaccine candidates and support clinical trials involving vaccine candidates.

West Coast Consortium for Technology & Innovation in Pediatrics (CTIP)

West Coast Consortium for Technology & Innovation in Pediatrics (CTIP)

Topics: Pediatric medical device development or adaptation to manage the impact of COVID-19 on children

TD

TD Ready Challenge for COVID-19

Topics: TD supports innovative solutions that address the impacts of the pandemic, specifically for communities that are experiencing disproportionate impacts of COVID-19. TD seeks applications that will help drive accelerated, sustained and equitable recovery. Applications must work to explicitly address inequities exacerbated by the pandemic, primarily in health focus areas.

Johnson & Johnson

Drug Resistant Tuberculosis Lifeline QuickFire Challenge

Topics: Proposals should address one or more of the following topics:

• Remote consultations and follow-up
• Home-based and/or digital patient support for sustaining TB treatment adherence & completion
• Access to care for adverse events without leaving the home
• Connections to support mental health, nutrition, address social isolation, and peer-to-peer support as well as social benefit

Johnson & Johnson

Johnson & Johnson Nurses Innovate QuickFire Challenge in COVID-19 Patient Care

Topics:

• Treatment protocols
• Health technologies
• Medical devices
• Treatment approaches
• Consumer products
• Community health approaches
• Screening tools

23andMe

23andMe Research Innovation Collaborations Program for COVID-19

23andMe is now considering proposals focused on COVID-19. These proposals can include studies of outcomes, comorbidities, health disparities, and impacts of policies implemented to address the pandemic. If your proposal is related to COVID-19, please be sure to indicate this in your application. We are anticipating a high volume of COVID-19-related proposals, and our team of scientific reviewers is committed to selecting proposals where 23andMe’s participation will uniquely advance our understanding of this disease and the health of those impacted.

Merck KGaA Research Grants 

Aims to stimulate innovative research in challenging areas of future importance, including pandemic preparedness and fighting new emerging viral infectious diseases.

Agence Nationale de la Recherche (ANR)

Research Action COVID-19 (RA-COVID-19)

Topics:

• Epidemiological studies
• Physiopathogenesis of the disease
• Infection prevention and control
• Ethics and social dynamics
• Global issues of the Covid-19 epidemic

Women’s History Network

 Coronavirus hardship fund

This supports historians of women who are suffering financial hardship because of the coronavirus. A total of eight awards, worth £400 each, are available.

XPRIZE Foundation

XPRIZE Rapid Covid Testing

 Topics: The XPRIZE Foundation describes the competition as follows: “The winning teams will develop COVID-19 tests that are radically affordable compared to what’s currently available on the market. For about the price of a latte, the tests will be equal to (or better than) commercial offerings at measuring sensitivity, specificity, and limit of detection, with a maximum turnaround time of 12-hours from sample to result. The winning teams will also be able to successfully deploy and conduct a minimum of 500 tests per week at a live testing site within 60 days, and have the potential to scale their solutions to thousands of tests per week.

AMable/European Commission

AMable Open Call for Solution Ideas (COVID-19)

Topics: Challenges will involve a lack of equipment, helpful tools, replacement parts or parts that enable additional functionality.

Spanish Ministry of Science and Innovation

Solicitud Urgente de Expresiones de Interés para la Financiación Extraordinaria de Proyectos de Investigación sobre el SARS-CoV-2 y la Enfermedad COVID-19 (Spanish)

Topics:

• Scalable rapid diagnostic techniques for SARS-CoV-2, especially related to early stage detection and healthcare stratification
• Clinical, biological, and molecular characteristics of COVID-19
• Therapeutic development, including pharmaceutical and non-pharmaceutical measures
• Antiviral resistance studies
• Vaccine development
• Socioeconomic impact of COVID-19
• Integrated epidemiological controls, including AI and Big Data

Partnership for Advanced Computing in Europe

Support to mitigate the impact of COVID-19 pandemic

 This enables researchers to access computing resources to contribute to the mitigation of the impact of the COVID-19 pandemic. Access will be awarded for between three and six months and sized from 30 to 50 million core hours.

Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)

Emergency Action Projects to Combat the Effects of Covid-19 – FAPERJ / SES Partnership – 2020

Topics:

• Genomics
• Pathophysiology of the disease
• Clinical aspects
• Diagnosis of the disease
• Epidemiology
• Virus-host interaction
• Development of diagnostic kits
• Disease control and coping strategies
• Innovative solutions to expand supplies of items such as masks, alcohol gel, and respirators

UK Research and Innovation

COVID-19 Rapid Response Rolling Call

 Topics:

• Virology, immunity and pathophysiology
• Diagnostics
• Epidemiology
• Personal protective equipment
• Infection prevention and control measures
• Public Health, Media and Communication
• Clinical Management
• Primary, Adjunctive and Supportive Therapies
• Vaccines
• Health and care delivery
• Assays and animal models
• Research infrastructure

National Research Council Canada

National Research Council Industrial Research Assistance Program (NRC IRAP)

Topics: Development of COVID-19 solutions for health care workers and public health officials

Due Dates: None; applicants directly contact an Industrial Technology Advisor at NRC

Malta Council for Science and Technology and Malta Enterprise Corporation

COVID-19 R&D Fund

 Topics:

• Relevant medicinal products (including vaccines) and treatments, their intermediates, active pharmaceutical ingredients and raw materials
• Medical devices, hospital and medical equipment (including ventilators and protective clothing and equipment as well as diagnostic tools) and necessary raw materials
• Disinfectants and their intermediary products and raw chemical materials necessary for their production
• Data collection and processing tools related to innovative and/or improved approaches with regards to current and/or future infectious disease prevention; o trajectory of the epidemic/pandemic disease
• Better dissemination of recommendations by national (Public Health) and/or international health authorities (WHO)
• Any other research related to infectious diseases that can lead to epidemics in humans

Department of Health and Social Care including NIHR

Travel and subsistence funding to support LMIC engagement during the COVID-19 outbreak

 This provides travel and subsistence funding to appropriately qualified public health professionals, clinicians and academics who wish to offer science and technical advice to support the immediate response to COVID-19 in low and middle-income countries. Funding covers travel, accommodation and meals.

United Kingdom Government

TechForce19 – deploy technology to help vulnerable people isolated by COVID-19

 NHSX invites expressions of interest for the TechForce19 call. This enables innovators to test solutions that can support the elderly, vulnerable and self-isolating as COVID-19 continues to spread. The competition is aimed at helping in the community rather than seeking solutions that are trying to solve clinical problems or require integration with NHS systems.

 Japan International Cooperation Agency

NINJA Business Plan Competition

Topics: 

• Health: Online healthcare support; disease-testing solutions; medical data sharing and privacy protection solutions; distribution of drugs and medical equipment; IoT, including 3D printers, in the medical field
• Disaster management: Geo-tracking during disasters; emergency information dissemination
• Business services: Support for remote workers; efficient management/operation of online events
• Education sector: Remote learning support
• Food and agriculture: Efficient food/commodity distribution technology
• Finance: Contactless transactions/payment; lending/insurance services to SMEs and individuals
• Logistics: delivery service, urban mobility management
• Other: Substituting imported goods with local innovative technology